Evidence reveals that, CD133-targeted therapy of gastric, hepatocellular carcinoma (19), and glioblastoma (20) has greatly diminished cell proliferation and tumor growth within both in vitro and in vivo CD133POS-marker cells. This evidence concerns the gene PROM1 and glioblastoma.